title: bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up.
abstract: OBJECTIVE
  bcl-2 protein is detectable in human cancers and may be involved in the response to antineoplastic drugs or endocrine therapy in breast carcinomas. In a previous study, we had developed optimal technical conditions for bcl-2 immunodetection. The aim of the present report was to determine the prognostic significance of bcl-2 expression in breast carinomas by the use of a similar immunocytochemical procedure.
  
  
  METHODS
  bcl-2 immunocytochemical assays were performed on frozen sections by automated immunoperoxidase technique (Ventana) and computer-assisted analysis of digitized colored microscopic images (SAMBA) in a series of 170 breast carcinomas. The results of automated quantitative immunocytochemical assays were correlated with patient follow-up (120 months).
  
  
  RESULTS
  Intense bcl-2 immunocytochemical expression in tumors (cutpoint, 15%) significantly correlated with longer disease-free survival and longer recurrence-free survival in the entire cohort of patients (P = .028 and P = .035, respectively) and also in node-negative subgroups of patients (P = .028 and P = .01; Kaplan-Meier long-rank test; NCSS 6.0.1 software). But bcl-2 immunostained surfaces (cutpoint, 15%) did not correlate with overall survival. In multivariate analysis (proportional hazards regression, Cox model), bcl-2 prognostic significance in terms of disease-free survival was only independent of the tumor size and grade and histoprognostic index (Nottingham prognostic index [NPI]).
  
  
  CONCLUSIONS
  bcl-2 immunohistochemical expression is a significant indicator of favorable outcome only in terms of disease-free and local recurrence-free survival. However, bcl-2 expression in tumors is an independent weakly prognostic indicator in breast carcinomas. bcl-2 immunodetection assessed in optimal technical conditions (frozen samples, automation, quantitative analysis, scatter diagram cutoffs) may have some limited practical clinical relevance for the management of patients with breast carcinomas.
authors.affiliation: Department of Pathology, Faculté de Médecine Timone, Institut Fédératif de Recherche en Cancérologie et Immunologie de Marseille, France. denis.charpin@wanadoo.fr
authors.forename: C
authors.initials: C
authors.lastname: Charpin
authors.forename: S
authors.initials: S
authors.lastname: Garcia
authors.forename: P
authors.initials: P
authors.lastname: Bonnier
authors.forename: F
authors.initials: F
authors.lastname: Martini
authors.forename: L
authors.initials: L
authors.lastname: Andrac
authors.forename: N
authors.initials: N
authors.lastname: Horschowski
authors.forename: M N
authors.initials: MN
authors.lastname: Lavaut
authors.forename: C
authors.initials: C
authors.lastname: Allasia
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2